Clinical trial NCT06845878: A Chatbot to Support Substance Use Recovery
Official title: A Conversational Agent to Support Follow-up Care for Individuals in Recovery for Substance Use Disorder
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
PHASE2
Conditions: Opiate-Related Disorders
Opiate Substitution Treatment
Lead sponsor: Dimagi Inc.
Sponsor class: INDUSTRY
Collaborators: name: National Institute on Drug Abuse (NIDA)
name: University of California, Los Angeles
name: Massachusetts General Hospital
First posted: 2025-02-25
Enrollment: 55
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Pre-Post Intervention
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The goal of this clinical trial is to learn if/how an AI chatbot can support patients who in recovery for substance use, specifically those who are receiving medication for opioid use disorder.

Can the chatbot help lower drug use? Can the chatbot help improve clinical appointment adherence? Can the chatbot help patients build self-efficacy in leading their own recovery journey? Will the chatbot help reduce workload burden for primary care teams? Can the chatbot serve as a safe, useful and engaging tool to support patients?

Researchers will investigate the effects of using a chatbot to support follow-up care for patients in opioid use recovery.

Participants will:

* Receive access to a chatbot for 12 weeks that they can use to prepare for upcoming clinical appointments, find community resources, learn about urge-surfing and wellness techniques, and query for assistance with other recovery-related information and tasks
* Complete surveys and provide user feedback


Eligibility criteria: Inclusion Criteria:

* 18-65 years old
* Comfortable with reading, understanding, and communicating in English
* Receiving medication treatment for OUD at MGH?
* Able to participate in a remote interview?
* Own or have reliable access to Wi-Fi or a cellular network
* Willing to use a mobile device to access the chatbot?

Exclusion Criteria:

* Has any cognitive, visual, or auditory impairments that may prevent the participant from using the chatbot on a mobile device?
* Unstable medical condition that compromises the ability to safely participate

Primary outcomes:
measure: Change in SUD severity
timeFrame: 12 weeks
measure: Change in psychological health (Anxiety)
timeFrame: 12 weeks
measure: Change in psychological health (Depression)
timeFrame: 12 weeks
measure: Change in self-efficacy for managing chronic conditions (Emotions)
timeFrame: 12 weeks
measure: Change in self-efficacy for managing chronic conditions (Social Interactions)
timeFrame: 12 weeks
Secondary outcomes:
measure: Change in quality of life
timeFrame: 12 weeks
measure: Change in social needs
timeFrame: 12 weeks
measure: Chatbot usability
timeFrame: End of 12 week intervention
measure: User Satisfaction
timeFrame: End of 12 week intervention
Other outcomes:
Locations:
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
Study officials:
affiliation: Dimagi Inc.
name: Y. Xian Ho, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Dimagi Inc.
name: Jonathan Jackson, MEng
role: PRINCIPAL_INVESTIGATOR
References: